Clinical MAPPs: a personalized healthcare-driven assay for the direct identification of potential T cell epitopes in patients

The development of anti-drug antibodies (ADAs) in response to therapeutic monoclonal antibody (mAb) treatments can undermine their efficacy and safety. A key player in this immunogenicity is the presentation of mAb-derived peptides by dendritic cells, which activates CD4+ T-helper cells. Traditional...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Katharina Hartman, Guido Steiner, Cary M. Looney, Michel Siegel, Katharine Bray-French, Klaudia Brix, Sebastian Springer, Timothy P. Hickling, Niels Janssen, Axel Ducret, Céline Marban-Doran
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Frontiers Media S.A. 2026-07-01
Schriftenreihe:	Frontiers in Immunology
Schlagworte:	anti-drug antibodies dendritic cells immunogenicity MAPPs assay mass spectrometry personalized healthcare
Online-Zugang:	https://www.frontiersin.org/articles/10.3389/fimmu.2026.1879253/full
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!